42
Participants
Start Date
August 1, 2022
Primary Completion Date
August 1, 2025
Study Completion Date
August 1, 2025
Inotuzumab Ozogamicin
intravenous infusion: Cycle 1: D1 0.8mg/m2, D8 0.5mg/m2, D15 0.5mg/m2, if the MRD turn negative, cycle 2: D1 0.5mg/m2, D8 0.5mg/m2, D15 0.5mg/m2， if not，cycle 2: D1 0.8mg/m2, D8 0.5mg/m2, D15 0.5mg/m2
RECRUITING
The First Affiliated Hospital of Soochow University, Suzhou
Jining Medical University
OTHER
The Second People's Hospital of Huai'an
OTHER
The First Affiliated Hospital of Bengbu Medical University
OTHER
Affiliated Hospital of Nantong University
OTHER
Suzhou Hospital of Traditional Chinese Medicine
OTHER
Northern Jiangsu People's Hospital
OTHER
Sheng-Li Xue, MD
OTHER